Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (20719)	5/13/1998 9:32:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

Andy, I've been hoping for that. Perhaps, at the upcoming conference. Beating Tamoxifen by 100%, in ugly, naked mice, if hyped correctly, could do wonders. I have made about 6 bad predictions in a row, but....... I think that LGND's stock might jump up quite a bit on the NDA filing for Panretin Topical. It's the first topical ointment treatment for cancer! Even though they are only getting approval for KS, to me, it has much greater possibilities. Plus, if it is hyped correctly, the public might react. But, would a doctor use Panretin, off label, for the treatment of skin cancel? I don't know. It could be used, perhaps, as additional protection. First, remove the cancer thru surgery, and then treat with Panretin as additional insurance!? Good luck, Bob

To: Andrew H who wrote (20719)	5/13/1998 10:21:00 PM
From: HerbertOtto	Read Replies (1) \| Respond to of 32384

Andy, LGND and Cancer results - 5 drugs in the works. But it can't be rats... it has to be MICE. Speculators respond to mice - not rats, not human studies like Ph II or Ph III - just MICE. --- Got it? <g> Good luck, Herbert